MedTrace Logo

Levosimendan Administration in Pulmonary Hypertension

NCT04599816 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-02-08

No results posted yet for this study

Summary

The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right ventricular function.

Conditions

  • Hypertension, Pulmonary
  • Cardiac Failure
  • Pulmonary Vascular Resistance Abnormality

Interventions

DRUG

levosimendan at a dose of 3 mcg/kg

levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction

DRUG

levosimendan at a dose of 6 mcg/kg

levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction

DRUG

levosimendan at a dose of 12 mcg/kg

levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction

Sponsors & Collaborators

  • Aretaieion University Hospital

    lead OTHER

Principal Investigators

  • Kassiani Theodoraki, PhD, DESA · Aretaieion University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2022-10-17
Completion
2022-10-17

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04599816 on ClinicalTrials.gov